FDA Approves Olutasidenib For Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
On December 1, 2022, the Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. Read more.